ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Myovant Sciences Ltd

Myovant Sciences Ltd (MYOV)

26.98
0.00
(0.00%)
Closed September 24 4:00PM
0.00
0.00
(0.00%)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
26.98
Bid
-
Ask
-
Volume
-
0.00 Day's Range 0.00
26.98 52 Week Range 26.98
Previous Close
26.98
Open
-
Last Trade
Last Trade Time
Average Volume (3m)
-
Financial Volume
-
VWAP
-

MYOV Latest News

Myovant Sciences Announces Corporate Updates and Financial Results for Third Fiscal Quarter 2022

Third fiscal quarter 2022 total revenue of $100.2 million; including net product revenue of $61.4 millionNet product revenue from U.S. sales of ORGOVYX® of $48.7 million in third fiscal quarter...

MYOV SPECIAL ALERT: Julie & Holleman Investigates Potential Legal Claims Related to Take-Private Acquisition of Myovant Sciences

MYOV SPECIAL ALERT: Julie & Holleman Investigates Potential Legal Claims Related to Take-Private Acquisition of Myovant Sciences PR Newswire NEW YORK, Dec. 16, 2022 NEW YORK, Dec. 16, 2022...

Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08

BASEL, Switzerland, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven...

Myovant Sciences Appoints Ann Tomlin as Senior Vice President of Human Resources

BASEL, Switzerland, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) today announced the appointment of Ann Tomlin as Senior Vice President of Human Resources. Beginning November...

Myovant Sciences Announces Corporate Updates and Financial Results for Second Fiscal Quarter 2022

On October 23, 2022, Sumitovant Biopharma Ltd. (Sumitovant), in conjunction with parent company Sumitomo Pharma Co., Ltd. (Sumitomo Pharma), and Myovant Sciences (Myovant) announced that they have...

Myovant Sciences Cancels Second Quarter Earnings Conference Call

BASEL, Switzerland, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) (“Myovant”) today announced the cancellation of its earnings conference call for the quarter ended September...

Sumitovant Biopharma, Sumitomo Pharma, and Myovant Sciences Enter into Definitive Agreement

Sumitovant Biopharma to Acquire all Outstanding Shares of Myovant for $27 Per Share in Cash Combination Provides Expertise and Resources to Address Unmet Patient Needs in Women’s Health and...

Sumitovant Biopharma, Sumitomo Pharma, and Myovant Sciences Enter into Definitive Agreement

Sumitovant Biopharma, Sumitomo Pharma, and Myovant Sciences Enter into Definitive Agreement PR Newswire NEW YORK and BASEL, Switzerland and OSAKA, Japan, Oct. 23, 2022 Sumitovant Biopharma to...

Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08

BASEL, Switzerland, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven...

CORRECTION -- Myovant Sciences, Inc.

BASEL, Switzerland, Oct. 14, 2022 (GLOBE NEWSWIRE) -- In a release issued under the headline "Myovant Sciences to Host Second Fiscal Quarter 2022 Earnings Conference Call at 5:00 p.m." earlier...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10026.9826.9826.9800CS
40026.9826.9826.9800CS
120026.9826.9826.9800CS
260026.9826.9826.9800CS
520026.9826.9826.9800CS
1563.8216.49395509523.1627.067.6747356720.07862432CS
26021.22368.4027777785.7630.89994.1474879618.10521675CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
MKFGMarkforged Holding Corporation
$ 2.53
(32.46%)
980.88k
AMPXAmprius Technologies Inc
$ 1.11
(24.86%)
4.43M
MPLNChurchill Capital Corp III
$ 8.91
(18.42%)
337.05k
DNMRDanimer Scientific Inc
$ 0.3775
(16.15%)
752.86k
FEDUFour Seasons Education Cayman Inc
$ 10.07
(14.17%)
11.91k
PNSTPinstripes Holdings Inc
$ 0.70
(-21.47%)
112.48k
MNSOMINISO Group Holding Limited
$ 13.71
(-16.71%)
17.37M
EVTLVertical Aerospace Ltd
$ 5.62
(-14.85%)
124.5k
UPWheels Up Experience Inc
$ 2.03
(-13.98%)
1.34M
BPTBP Prudhoe Bay Royalty Trust
$ 1.11
(-11.90%)
440.27k
PLTRPalantir Technologies Inc
$ 37.95
(2.02%)
79.46M
NIONIO Inc
$ 5.325
(0.85%)
66.29M
BBDBanco Bradesco SA
$ 2.565
(-2.47%)
50.42M
FFord Motor Company
$ 10.91
(0.28%)
40.42M
SNAPSnap Inc
$ 10.20
(1.49%)
35.57M

MYOV Discussion

View Posts
Cosa Cosa 2 years ago
What a run from the $7's a few months back. Closed my entire position on Tuesday. Sitting on powder ready to go. ARDX looking really strong right now coming off its lows with some upcoming catalyst.
👍️0
MDizzle MDizzle 2 years ago
I was hoping for $5. more a share but a win is a win haha
👍️0
Cosa Cosa 2 years ago
Woohoo Cheers!!
👍️0
Cosa Cosa 2 years ago
Woohoo Cheers!!
👍️0
Cosa Cosa 2 years ago
Nice! patience always pays. Agree it will lose some steam quickly. Half my position is gone, will add if it goes back down below $13's. Hopefully it does get a bigger offer, but not waiting for that to happen.

Followed
👍️0
Cosa Cosa 2 years ago
Lol. No worries it will make a comeback. Even though management is quite, they need the share price up. They're options are worthless at this point. Just need to be patient. Good Luck!
👍️0
Dallas-Cowboys Dallas-Cowboys 2 years ago
I also took profits on most of the shares I owned I have been in this for quite awhile at $21.40 I always thought Pfizer would buy this but when I read Sumo said they would not sell their shares that changed my thinking. I didn’t make much for the amount of time I held but I was under water for along time wondering if I would just break even. If they don’t raise their bid this will crash
👍️0
rosemountbomber rosemountbomber 2 years ago
Yep taking profits here as don't want to be burned like with AUPH.
👍️0
Cosa Cosa 2 years ago
Taking more off the top. What a great day here!
👍️0
nferna nferna 2 years ago
The tell in that sad situation was the insider sales near the top. (Wish I had paid more attention to that, major lesson learned)
👍️0
Dallas-Cowboys Dallas-Cowboys 2 years ago
What we will see is if Pfizer wants to partner with Sumo or do they want the whole thing. If so they have to buy all the shares and Sumo will be in the drivers seat . Should become interesting
👍️0
Dallas-Cowboys Dallas-Cowboys 2 years ago
Sorry to hear that I don’t think this is the same situation. They low balled probably knowing it wouldn’t fly, there are 3 Sumo people on Myov board. They will sweeten the offer now how much who knows but we will see soon enough
👍️0
rosemountbomber rosemountbomber 2 years ago
I have tried to put all the details of that sordid story behind me, but basically last Fall, Bristol Meyers was set to buy Aurinia. Financial officer released the story and then quickly erased it and was later fired, but ultimately the CEO thought the deal was not good enough and things went south from there. Then of course sales of their very expensive drug have gone nowhere and stock cratered to 1/5 of supposed deal price.
👍️0
Dallas-Cowboys Dallas-Cowboys 2 years ago
Not aware of that what happened
👍️0
rosemountbomber rosemountbomber 2 years ago
Hope there is no screw up like Peter Greenleaf with Aurinia.
👍️0
Dallas-Cowboys Dallas-Cowboys 2 years ago
That would value around 2.3 billion no way too cheap they know it
👍️0
DewDiligence DewDiligence 2 years ago
Maybe. The problem (for MYOV minority shareholders) is that Sumitovant can play hardball and force the issue if they choose to do so.
👍️0
Dallas-Cowboys Dallas-Cowboys 2 years ago
It is just getting started first volley they already turned it down. They will be coming back higher and hopefully this will get Pfizer off the fence. Getting interesting
👍️0
DewDiligence DewDiligence 2 years ago
https://finance.yahoo.com/news/myovant-sciences-special-committee-board-233600693.html

I warned against exactly this kind of “takeunder” in #msg-167606619.
👍️0
Dallas-Cowboys Dallas-Cowboys 2 years ago
I believe they want to be taken over now they might not want a hostile takeover but why do we care if SP goes up
👍️0
Cosa Cosa 2 years ago
Either way they are going to make a killing. What a great position to be in. They keep adding shares too. As long as it is not a hostel takeover, that would be catastrophic for retail.
👍️0
Dallas-Cowboys Dallas-Cowboys 2 years ago
Yes Sumo owns 53% and has 3 board members so it will be their decision. So if Pfizer does want it at $40 to $50 a share that is a lot of cash for Sumo. Otherwise they will have to wait until myovant grows their revenue and turns profitable.
👍️0
Cosa Cosa 2 years ago
With Sumitomo owning the majority of shares it will be up to them if they want to sell or not.
👍️0
Dallas-Cowboys Dallas-Cowboys 2 years ago
With their share count at around 100 million approximately 5 billion buyout definitely in Pfizer’s wheelhouse
👍️0
rosemountbomber rosemountbomber 2 years ago
So you are looking for a BO at close to $50 per share?
👍️0
Dallas-Cowboys Dallas-Cowboys 2 years ago
Yes Sumo owns majority and some people think they will eventually buy the rest but I’m not in that camp. I think Pfizer will be the suitor. They are in the buying mode in that 5 billion range which myov will fall into imo
👍️0
Cosa Cosa 2 years ago
Sumitomo owns most of the shares, so there is hardly any shares for the public. Price can really move with little volume. The increasing revenue and recent nod from FDA also a factor. The partnership with PFE was a great idea, the long arms of BP can really move a product.
👍️0
Cosa Cosa 2 years ago
Took a little more off the table today. MYOV! $7 back in May, what a nice come back from yearly low.
👍️0
Dallas-Cowboys Dallas-Cowboys 2 years ago
Listened to the conference yesterday seemed run of the mill no questions or mention of buyout. Sure didn’t explain run any theories here?
👍️0
rosemountbomber rosemountbomber 2 years ago
Difficult to believe we wouldn't see 52 week highs. Another approval and sales climbing.
👍️0
Cosa Cosa 2 years ago
Nice break to the upside!
👍️0
Cosa Cosa 2 years ago
Consolidating the past few weeks. Which way is it going to break....
👍️0
Cosa Cosa 2 years ago
Took some profits today. Looking really bulllish!
👍️0
rosemountbomber rosemountbomber 2 years ago
Any guess as to what to expect in premarket Monday?

Glad I swung my AUPH money over here a couple of weeks ago adding to my position here I started in the Spring.
👍️0
Cosa Cosa 2 years ago
MYFEMBREE FDA Approved! Looking forward to Monday!
👍️0
Cosa Cosa 2 years ago
Those bargain prices from a few months back is up 70%!
👍️0
Cosa Cosa 2 years ago
Up and to the right.
👍️0
Cosa Cosa 2 years ago
If volume comes back this will blast off.
MYOV!
👍️0
Cosa Cosa 2 years ago
Go baby go!! MYOV! Going up on really low volume. Not sure if we can hold these gains.
👍️0
DewDiligence DewDiligence 2 years ago
The deal terms were not better than expected, so the sell-off is not especially surprising on a day like today.
👍️0
Cosa Cosa 2 years ago
Good news does nothing in fearful market. 7's...wow, trading like phase 2 company with no FDA approved drugs.
👍️0
Cosa Cosa 2 years ago
I'm holding bags for sure lol
👍️0
DewDiligence DewDiligence 2 years ago
MYOV bags European partner for Orgovyx:

https://www.globenewswire.com/news-release/2022/05/09/2438369/0/en/Myovant-Sciences-and-Accord-Healthcare-Ltd-Enter-into-Exclusive-License-Agreement-to-Commercialize-ORGOVYX-for-Advanced-Hormone-Sensitive-Prostate-Cancer-in-Europe.html Myovant Sciences and Accord Healthcare, Ltd. (Accord) today announced that they have entered into an exclusive license agreement for Accord to commercialize relugolix for the treatment of advanced hormone-sensitive prostate cancer under the trade name ORGOVYX (relugolix, 120 mg) in the European Economic Area, United Kingdom, Switzerland and Turkey…

…Under the terms of the agreement, Myovant will receive an upfront payment of $50 million and is eligible to receive commercial launch, sales-based and other milestones totaling up to $90.5 million. In addition, Myovant is eligible to receive tiered royalties from the high-teens to mid-twenties on net sales.
👍️0
Cosa Cosa 2 years ago
Cheers Bro! buying the dip in both
👍️0
winepro1 winepro1 2 years ago
Cosa,
I see you are also into MYOV. I no longer post on AUPH as I am tired of BR, Cervelo, Whalatane, and Rosemount bomber, who I suspect are all questionable posters and now dominate a once good site. I was there due to Vidpok. You, zzaatt, and moosedogger would probably appreciate stocktwits AUPH much more. There is a good amount of fud posters but also some serious posters also that dig up much more good info. Just wanted to let you know.
Winepro1, ( aka HarryCrumb).
👍️0
Cosa Cosa 2 years ago
I think you're taking the smarter approach. I'm putting myself in a higher risk higher reward situation. Nothing a few drinks can't fix lol.
👍️0
randychub randychub 2 years ago
Hoping I don’t miss the boat but I’m waiting for the FDA letter
👍️0
Cosa Cosa 2 years ago
Market cap below $1B. 2 year low. I bought more at $9.64 averaging down. Back in 2019 it went from high of $26 down to $4.50. I wonder if that is going to this year. Bio's keep getting hammered.
👍️0
DewDiligence DewDiligence 2 years ago
There is still time for the FDA to deliberate about the problem in question between now the 5/6/22 PDUFA date.
👍️0
randychub randychub 2 years ago
“The FDA noted that the letter does not reflect a final decision on the pending sNDA and that the application is still under review”

Any thoughts on why the FDA has not yet given a final decision?
👍️0

Your Recent History

Delayed Upgrade Clock